Kailera Therapeutics, Inc.
KLRA evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Market Cap:
- $2.13B
- Lead Asset:
- kai-4729
What it means
What to watch
Prepared research question
What matters most for KLRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KLRA
Kailera Therapeutics, Inc. (KLRA) is a clinical-stage biotechnology company developing GLP-1/GIP receptor dual agonists for obesity and related conditions, with its lead candidate ribupatide in Phase 3 trials and topline data expected in mid-2028.
Key risk: Long timeline to Phase 3 data
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.13B
Cash Runway
—
Lead Asset
kai-4729
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for Kailera Therapeutics, Inc..
Kailera Therapeutics, Inc. (KLRA) is a clinical-stage biotechnology company developing GLP-1/GIP receptor dual agonists for obesity and related conditions, with its lead candidate ribupatide in Phase 3 trials and topline data expected in mid-2028.
- Lead candidate ribupatide (KAI-9531) is a GLP-1/GIP receptor dual agonist in Phase 3 for obesity, with topline data expected in mid-2028 [news · 2026-09-30].
- Cash & equivalents of $130.3M as of 2026-06-30 [sec].
- Net loss of -$111.3M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $1,118.5M as of 2026-06-30 [sec].
- Phase 2 trial of oral candidate KAI-7535 for obesity initiated in April 2026 [catalyst].
What works
- Three GLP-1 candidates in development, providing pipeline breadth [news · 2026-09-17].
- Phase 3 enrollment completed for ribupatide, indicating clinical momentum [news · 2026-09-30].
- Strong cash position of $130.3M as of 2026-06-30 supports ongoing trials [sec].
- Appointment of experienced executives (CTO, CCO) suggests preparation for commercialization [news · 2026-08-11][news · 2026-06-29].
What to weigh
- Net loss of -$111.3M as of 2026-06-30 reflects high R&D spending [sec].
- Topline data for lead candidate ribupatide not expected until mid-2028, a long timeline [news · 2026-09-30].
- Differentiation from existing GLP-1 drugs remains unproven; efficacy data needed [news · 2026-09-18].
- Oral candidate KAI-7535 is only in Phase 2, with no near-term catalyst [catalyst].
From the filings
Quoted directly from source documents.
Lead candidate ribupatide Phase 3 enrollment completed; topline data mid-2028
“Topline data now expected in mid-2028”
News · September 30, 2026
Catalyst timeline
- 2026-04-06 · Phase 2 start for oral KAI-7535 — Phase 2 trial of oral KAI-7535 for obesity initiated; no results yet.
Risks & what to watch (3)›
Key risks
- Long timeline to Phase 3 data — Topline data for ribupatide not expected until mid-2028, delaying potential approval [news · 2026-09-30].
- Unproven differentiation — Need for progress on weight loss differentiation from existing GLP-1 drugs [news · 2026-09-18].
- Significant net loss — Net loss of -$111.3M as of 2026-06-30 indicates high cash burn [sec].
What to watch
- Mid-2028 topline data from the KaiNETIC Phase 3 program for ribupatide [news · 2026-09-30].
- Phase 2 results for oral candidate KAI-7535, initiated April 2026 [catalyst].
- Any new clinical data or regulatory milestones for ribupatide or other pipeline candidates [news · 2026-10-01].
- Cash runway and spending rate given net loss of -$111.3M as of 2026-06-30 [sec].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Kailera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kailera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Kailera Therapeutics, Inc.?
Kailera Therapeutics, Inc. (KLRA) is a clinical-stage biotechnology company developing GLP-1/GIP receptor dual agonists for obesity and related conditions, with its lead candidate ribupatide in Phase 3 trials and topline data expected in mid-2028.
Who is the CEO of Kailera Therapeutics, Inc.?
Mr. Ronald C. Renaud Jr., M.B.A. is the chief executive officer of Kailera Therapeutics, Inc. (KLRA).
Where is Kailera Therapeutics, Inc. headquartered?
Kailera Therapeutics, Inc. (KLRA) is headquartered in Waltham, MA, United States.
What therapeutic areas does Kailera Therapeutics, Inc. focus on?
Kailera Therapeutics, Inc. develops therapies across Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.